全球穿戴式连续血糖监测仪市场 - 2025 至 2033 年

2024 年全球穿戴式连续血糖监测仪 (CGM) 市场规模达到 45.7 亿美元，预计到 2033 年将达到 166 亿美元，在 2025-2033 年预测期内的复合年增长率为 15.5%。

穿戴式连续血糖监测仪 (CGM) 是用于即时监测血糖水平的先进医疗设备。它们提供全天血糖波动的连续即时资料，与提供单点读数的传统血糖仪相比，提供更详细、更一致的血糖水平图像。

市场动态：

驱动因素与约束因素

糖尿病盛行率上升

全球糖尿病盛行率的大幅上升推动了可穿戴连续血糖监测 (CGM) 设备市场的成长。根据世界卫生组织的数据，糖尿病患者数量急剧增加，从 1990 年的 2 亿增加到 2022 年的 8.3 亿，其中成长最快的是中低收入国家。随着糖尿病盛行率的上升，对血糖水平进行有效、即时监测的需求变得更加迫切。穿戴式 CGM 为持续血糖监测提供了一种有效、非侵入性的解决方案，帮助患者更好地管理病情并降低严重併发症的风险。

未经治疗或管理不当的糖尿病影响非常严重，可导致失明、肾衰竭、心臟病、中风和下肢截肢等病症。光是 2021 年，糖尿病和糖尿病相关肾病变就导致超过 200 万人死亡，高血糖导致心血管死亡人数约 11%。根据这些统计数据，随着医疗保健系统和患者寻求更积极的方式来管理糖尿病和预防危及生命的併发症，对连续血糖监测设备的需求预计会增加。

穿戴式 CGM 在为个人提供即时资料方面变得越来越重要，这些数据可以帮助及时采取干预措施、降低併发症风险并改善糖尿病患者的整体生活品质。糖尿病管理日益增长的需求是推动穿戴式 CGM 市场扩张的关键因素。

感测器更换成本高

穿戴式连续血糖监测 (CGM) 设备的感测器寿命短和更换成本会给消费者带来经济负担，从而严重限制市场。大多数 CGM 感测器需要每 7 到 14 天更换一次，导致频繁的持续费用迅速累积，使长期使用成本高昂。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

• 影响因素
  • 驱动程式
    • 糖尿病盛行率上升
  • 限制
    • 感测器更换成本高
  • 机会
• 影响分析

第五章：战略洞察与产业展望

• 市场领导者和先驱者
  • 新兴先锋和杰出参与者
  • 拥有最大销售品牌的成熟领导者
  • 拥有成熟产品的市场领导者
• CXO 观点
• 最新进展与突破
• 案例研究/正在进行的研究
• 监管和报销情况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
• 波特五力分析
• 供应链分析
• 专利分析
• SWOT 分析
• 未满足的需求和差距
• 市场进入和扩张的推荐策略
• 情境分析：最佳情况、基本情况和最坏情况预测
• 定价分析和价格动态
• 关键意见领袖

第 6 章：按类型

• 1 型糖尿病
• 2 型糖尿病

第 7 章：按组件

• 感应器
• 发射器和接收器
• 显示器
• 其他的

第 8 章：依年龄组

• 孩子们
• 成年人
• 长老

第 9 章：按最终用户

• 家庭护理设置
• 医院和诊所
• 其他的

第 10 章：按地区

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
• 亚太
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 中东和非洲

第 11 章：竞争格局

• 竞争格局
• 市场定位/份额分析
• 併购分析

第 12 章：公司简介

• Afon Technology
• 公司概况
• 产品组合
  • 产品描述
  • 产品关键绩效指标 (KPI)
  • 历史和预测产品销售量
  • 产品销售量
• 财务概览
  • 公司收入
  • 地区收入份额
  • 收入预测
• 主要进展
  • 合併与收购
  • 关键产品开发活动
  • 监管部门批准等
• SWOT 分析
• Abbott
• Senseonics
• Ascensia Diabetes Care Holdings AG.
• A. Menarini Diagnostics srl
• Murata Manufacturing Co., Ltd.
• Dexcom, Inc.
• Tandem Diabetes Care, Inc.
• Medtronic
• Byram Healthcare Centers, Inc.
• Similar data will be provided for each market player.

第 13 章：附录

The global wearable continuous glucose monitors (CGM) market reached US$ 4.57 billion in 2024 and is expected to reach US$ 16.60 billion by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Wearable Continuous Glucose Monitors (CGMs) are advanced medical devices used to monitor glucose levels in real time. They provide continuous, real-time data on glucose fluctuations throughout the day, offering a more detailed and consistent picture of glucose levels compared to traditional blood glucose meters that provide single-point readings.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The significant rise in the global prevalence of diabetes is driving the growth of the wearable continuous glucose monitoring (CGM) devices market. The number of people living with diabetes has increased dramatically, from 200 million in 1990 to 830 million in 2022, with the most rapid rise occurring in low- and middle-income countries according to the World Health Organization. As the prevalence of diabetes grows, the need for effective, real-time monitoring of glucose levels becomes even more critical. Wearable CGMs offer an efficient, non-invasive solution for continuous glucose monitoring, helping patients better manage their condition and reduce the risk of severe complications.

The impact of untreated or poorly managed diabetes is severe, leading to conditions such as blindness, kidney failure, heart attacks, strokes, and lower limb amputations. In 2021 alone, diabetes and diabetes-related kidney disease were responsible for over 2 million deaths, with high blood glucose contributing to around 11% of cardiovascular deaths. Given these statistics, the demand for continuous glucose monitoring devices is expected to increase as healthcare systems and patients seek more proactive ways to manage diabetes and prevent life-threatening complications.

Wearable CGMs are becoming increasingly vital in providing individuals with real-time data that can inform timely interventions, reduce the risk of complications, and improve the overall quality of life for people with diabetes. This growing need for diabetes management is a key factor driving the expansion of the wearable CGM market.

High Sensor Replacement Costs

The short sensor lifespan and replacement costs of wearable continuous glucose monitoring (CGM) devices can significantly restrain the market by creating a financial burden for consumers. Most CGM sensors need to be replaced every 7 to 14 days, resulting in frequent ongoing expenses that can quickly add up, making long-term use costly.

Segment Analysis

The global wearable continuous glucose monitors (CGM) market is segmented based on type, components, age group, end-user, and region.

Product Type:

Sensors segment is expected to dominate the global wearable continuous glucose monitors (cgm) market share

The sensors component segment is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to their essential role in providing real-time, accurate glucose measurements. Sensors are the core technology behind CGMs, as they continuously monitor blood glucose levels through interstitial fluid, offering users detailed and up-to-date information. With the increasing demand for more precise, real-time monitoring, advancements in sensor technology have enabled the development of more accurate, smaller, and longer-lasting devices.

Moreover, innovations in sensor design, such as improved accuracy, reduced size, and extended wear times, are driving the segment's growth. As people with diabetes seek more efficient and convenient ways to manage their condition, the demand for CGM systems with advanced sensors is growing. This makes the sensors segment a key driver in the wearable CGM market, as it directly impacts the overall performance and reliability of these devices.

Geographical Analysis

North America is expected to hold a significant position in the global wearable continuous glucose monitors (CGM) market share

North America is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to a combination of factors. The increasing technological advancements, rising number of diabetic patients, and increasing number of product launches are expected to hold the region in the dominant position in the global market.

The region has a high prevalence of diabetes, driving the demand for advanced diabetes management solutions. The high incidence of diabetes in North America, particularly in the United States, is significantly driving the demand for wearable continuous glucose monitoring (CGM) devices. In 2021, an estimated 29.7 million people, or 8.9% of the U.S. population, were diagnosed with diabetes. This growing prevalence, including 352,000 children and adolescents under the age of 20, highlights the urgent need for effective and convenient ways to monitor glucose levels continuously. As the number of diabetes cases continues to rise, the demand for solutions like CGMs, which provide real-time, accurate glucose data and help individuals manage their condition more effectively.

Additionally, market players are increasingly innovating the advanced wearable CGMs that are gaining approvals from the Food and Drug Administration (FDA). For instance, in March and June 2024, Dexcom and Abbott received clearance from the Food and Drug Administration (FDA) for their over-the-counter (OTC) continuous glucose monitors. While these devices utilize the same hardware as previous CGMs, they are designed for a different group of users, individuals who do not require insulin. Increasing approvals for products, such as over-the-counter continuous glucose monitors from companies are expected to drive the North American market by expanding accessibility to glucose monitoring solutions. This will cater to a broader range of users, including those without insulin dependence. Thus, the above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the wearable continuous glucose monitors (CGM) market include Afon Technology, Abbott, Senseonics, Ascensia Diabetes Care Holdings AG., A. Menarini Diagnostics srl, Murata Manufacturing Co., Ltd., Dexcom, Inc., Tandem Diabetes Care, Inc., Medtronic and Byram Healthcare Centers, Inc. among others.

Key Developments

• In September 2024, Abbott launched its latest wearable, the Lingo continuous glucose monitor, now available for over-the-counter purchase. Unlike traditional devices designed for diabetics, Lingo is tailored for health-conscious individuals who want to track their glucose levels without requiring prior medical approval.
• In February 2024, Know Labs, Inc. unveiled the KnowU, its wearable non-invasive continuous glucose monitor (CGM). The company first introduced the prototype in June 2023, with the KnowU being the outcome of an accelerated eight-month development process.
• In January 2025, Samsung announced that it is developing a highly anticipated feature for wearable technology: a non-invasive continuous glucose monitor.
• In April 2024, Senseonics Holdings, Inc. announced that their Eversense device has received the integrated CGM (iCGM) designation from the U.S. Food and Drug Administration (FDA).

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Wearable Continuous Glucose Monitors (CGM) Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Component
• 3.3. Snippet by Age Group
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Diabetes
  • 4.1.2. Restraints
    • 4.1.2.1. High Sensor Replacement Costs
  • 4.1.3. Opportunity
• 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Type 1 Diabetes*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Type 2 Diabetes

7. By Component

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 7.1.2. Market Attractiveness Index, By Component
• 7.2. Sensors*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Transmitters and Receivers
• 7.4. Displays
• 7.5. Others

8. By Age Group

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 8.1.2. Market Attractiveness Index, By Age Group
• 8.2. Children*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Adults
• 8.4. Elders

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Homecare Settings*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Hospitals & Clinics
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

• 12.1. Afon Technology*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Abbott
• 12.3. Senseonics
• 12.4. Ascensia Diabetes Care Holdings AG.
• 12.5. A. Menarini Diagnostics srl
• 12.6. Murata Manufacturing Co., Ltd.
• 12.7. Dexcom, Inc.
• 12.8. Tandem Diabetes Care, Inc.
• 12.9. Medtronic
• 12.10. Byram Healthcare Centers, Inc.
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us